Skip to main content
. 2013 Jun 5;18(6):675–684. doi: 10.1634/theoncologist.2012-0438

Figure 1.

Figure 1.

Flow diagram representing prospective trials investigating lapatinib among patients with metastatic breast cancer (A) prior to development of brain metastases [81], (B) immediately following the diagnosis of newly diagnosed brain metastases [20], or (C) following progression of disease following WBRT [21].

Abbreviations: C, capecitabine; CNS, central nervous system; L, lapatinib; TTP, time to progression of brain metastases; WBRT, whole brain radiation therapy.